Hostname: page-component-7c8c6479df-94d59 Total loading time: 0 Render date: 2024-03-29T05:29:25.125Z Has data issue: false hasContentIssue false

Homocysteine and stroke

Published online by Cambridge University Press:  01 February 2007

K Zaw*
Affiliation:
County Hospital, Griffithstown, Pontypool, Wales, UK
M T Hasan
Affiliation:
Caerphilly Miners' Hospital, Caerphilly, Wales, UK
B Bhowmick
Affiliation:
County Hospital, Griffithstown, Pontypool, Wales, UK
P B Khanna
Affiliation:
Nevill Hall Hospital, Abergavenny, Wales, UK
E A Freeman
Affiliation:
Royal Gwent Hospital, Newport, Gwent, Wales, UK
*
Address for correspondence: Khin Zaw, Torfaen Intermediate Care, County Hospital Coed-Y-Gric, Griffithstown, Pontypool, NP4 5YA, Wales, UK.

Extract

Interest in homocysteine's role in vascular disease was stimulated by the paper of McCully (1969) in which, based on autopsy evidence of extensive arterial thrombosis in two children with elevated plasma homocysteine concentrations and homocystinuria, he proposed that elevated plasma homocysteine (hyperhomocysteinaemia) can cause atherosclerotic vascular disease. A meta-analysis of subsequent prospective observational studies concluded that elevated homocysteine is indeed a modest independent predictor of ischaemic heart disease and stroke risk in healthy populations with a 25% reduction in serum homocysteine concentration, a reduction of approximately 3 micromol per litre (μmol/l) being associated with a 19% lower risk of stroke (odds ratio, 0.81; 95% confidence interval (CI), 0.69 – 0.95). In the nationally representative sample of US adults, elevated homocysteine concentration was independently associated with an increased likelihood of non-fatal stroke in both black and white adults. In this article, the current concepts relating homocysteine to ischaemic stroke are reviewed.

Type
Clinical geriatrics
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1McCully, KS. Vascular pathology of homocysteinaemia: implication for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111–28.Google Scholar
2Homocysteine Studies Collaboration. Homocysteine and risk of ischaemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015–22.CrossRefGoogle Scholar
3Giles, WH, Croft, JB, Greenland, KJ, Ford, ES, Kittner, SJ. Total homocysteine concentration and the likelihood of nonfatal stroke. Results from the third National Health and Nutrition Examination Survey, 1988–1994. Stroke 1998; 29: 2473–77.CrossRefGoogle ScholarPubMed
4Mayer, EL, Jacobsen, DW, Robison, K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27; 517–27.CrossRefGoogle ScholarPubMed
5Verhof, P, Stampfer, MJ, Buring, JE et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamin B6, B12 and folate. Am J Epidemiol 1996; 143: 845–59.CrossRefGoogle Scholar
6Rees, MM, Rodgers, GM. Homocysteinaemia : association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337–59.CrossRefGoogle Scholar
7Ubbink, JB. Assay methods for the measurement of total homocysteine in plasma. Semin Thromb Hemost 2006; 26: 233–41.CrossRefGoogle Scholar
8Ueland, PM, Refsum, H, Stabler, SP, Malinow, MR, Andersson, A, Allen, RH. Total homocysteine in plasma or serum : methods and clinical applications. Clin Chem 1993; 39: 1764–79.CrossRefGoogle ScholarPubMed
9Kang, SS, Wong, PW, Malinow, MR. Hyperhomocysteinaemia and risk factors for occlusive vascular disease. Ann Rev Nutr 1992; 12: 279–98.CrossRefGoogle Scholar
10Malinow, MR. Homocysteine, vitamins and genetic interaction in vascular disease. Can J Cardiol 1999; 15 (suppl B): 31B34B.Google ScholarPubMed
11Robinson, K, Mayer, E, Jacobson, DW. Homocysteine and coronary artery disease. Cleve Clin J Med 1994; 61: 438–50.CrossRefGoogle ScholarPubMed
12Brattstrom, L, Wilcken, DE, Onrik, J, Brudin, L. Common methylene tetrahydrofolate reductase gene metabolism leads to hyperhomocysteinaemia, but not to vascular disease: result of a meta-analysis. Circulation 1998; 98: 2520–26.Google Scholar
13Wilken, B, Bamforth, F et al. Geographical and ethnic variation of the 677 C → T allele of 5, 10 methyltetrahydrofolate reductase MTHFR: finding over 7000 newborns from 16 areas worldwide. J Med Genet 2003; 40: 619–25.CrossRefGoogle Scholar
14Frost, P, Bloom, HJ, Milos, R et al. A candidate genetic risk factor for vascular disease : a common mutation in methylene tetrahydrofolate reductase. Nat Genet 1995; 10: 111–13.CrossRefGoogle Scholar
15Bruschi, F, Daguati, R, Parazzini, F et al. Age, menopausal status and homocysteine levels in women around menopause. Eur J Obstet Gynaecol Reprod Biol 2005; 120: 195–97.Google Scholar
16Lindgren, A, Brattstrom, L, Norving, B, Hultberg, B, Anderson, A, Johansen, BB. Plasma homocysteine in the acute and convalescent phase after stroke. Stroke 1995; 26: 795800.CrossRefGoogle Scholar
17Meiklejohn, DJ, Vickers, MA, Dijkhuisen, R, Greaves, M. Plasma homocysteine concentration in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001; 32: 5762.Google Scholar
18Howard, VJ, Sides, EG, Newman, GC et al. Stability of Plasma Homocysteine in Acute Stroke Patients (SHASP) Study Investigators. Changes in plasma homocysteine in the acute phase after stroke. Stroke 2002; 33: 473–78.CrossRefGoogle Scholar
19Alfthan, G, Pekkanen, J, Jauhiainen, M et al. Relationship of serum homocysteine and lipoprotein concentrations to atherosclerotic disease in a prospective Finnish population-based study. Atherosclerosis 1994; 106: 919.CrossRefGoogle Scholar
20Verhoef, P, Hennekens, CH, Malinow, MR et al. A prospective study of plasma homocysteine and risk of ischaemic stroke. Stroke 1994; 25: 1924–30.CrossRefGoogle Scholar
21Nygard, O, Vollset, SE, Refsum, H, Stensvold, I et al. Total plasma homocysteine and cardiovascular risk profile : the Hordaland Homocysteine study. JAMA 1995; 274: 1526–33.Google Scholar
22Perry, IJ, Refsum, H, Morris, RW, Ebrahim, SB, Cleland, PM, Sharper, AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395–98.Google Scholar
23Toole, JF, Malinow, MR, Chamblers, LE et al. Lowering homocysteine in patients with ischaemic stroke to prevent recurrent stroke, myocardial infarction and death: the Vitamin Intervention for Stroke Prevention VISP randomised controlled trial. JAMA 2004; 291: 565–75.CrossRefGoogle Scholar
24Bots, ML, Launer, LJ, Lindemans, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly : the Rotterdam Study. Arch Intern Med 1999; 159: 3844.CrossRefGoogle ScholarPubMed
25Homocysteine Studies Collaboration. Homocysteine and risk of ischaemic heart disease and stroke. JAMA 2002; 288: 2015–23.CrossRefGoogle Scholar
26Bostom, AG, Rosenberg, IH, Silbershatz, H, Jacques, PF et al. Non-fasting plasma total homocysteine levels and stroke incidence in the elderly person: The Framingham Study. Ann Int Med 1999; 131: 352–55.CrossRefGoogle Scholar
27Eikelboom, JW, Hankey, GJ, Anand, SS, Lofthouse, E, Staples, N, Baker, RI. Association between high homocysteine and ischaemic stroke due to large- and small-artery disease but not other aetiologic subtypes of ischaemic stroke. Stroke 2000; 31: 1069–75.CrossRefGoogle ScholarPubMed
28Tan, NC-K, Vanketasubramanian, N, Saw, SM, Tjia, HTL. Hyperhomocysteinaemia and risk of ischaemic stroke among young Asian adults. Stroke 2002; 33: 1956–62.CrossRefGoogle ScholarPubMed
29Van Der Meer, IM, de Maat, MPM, Hak, AE et al. C reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree. The Rotterdam study. Stroke 2002; 33: 2750–55.Google Scholar
30Harker, LA, Stichter, SJ, Scott, CR, Ross, R. Homocysteinaemia: vascular injury and arterial thrombosis. N Eng J Med 1974; 291: 537–43.CrossRefGoogle Scholar
31Harker, LA, Ross, R, Stichter, SJ, Scott, CR. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731–41.Google Scholar
32Ratnoff, OD. Activation of Hageman factor by L-homocysteine. Science 1968; 162: 1007–9.CrossRefGoogle Scholar
33Rodgers, GM, Kane, WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909–16.Google Scholar
34Rodgers, GM, Conn, MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895901.Google Scholar
35Lentz, SR, Sadler, JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906–14.CrossRefGoogle Scholar
36Fryer, RH, Wilson, BD, Eubler, DB, Fitzgerald, LA, Rodgers, GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327–33.Google Scholar
37Nishinaga, M, Ozawa, T, Shimade, K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparin sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381–6.Google Scholar
38Tsai, JC, Wang, H, Perrella, MA et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97: 146–53.Google Scholar
39Hermann, W, Hermann, M, Obeid, R. Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 2007; 8: 1731.Google Scholar
40The Heart Outcome Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Eng J Med 2006; 354: 1567–77.Google Scholar
41Bonaa, KH, Njostad, I, Cleland, PM et al. Homocysteine-lowering and cardiovascular events after acute myocardial infarction. N Eng J Med 2006; 354: 1578–88.Google Scholar